Cure Genetics: Cure Genetics Raises $60 Million to Advance Universal CAR-T Products

Cure Genetics of Suzhou closed a $60 million Series B round to advance clinical development of its cell therapy candidates for hematological and solid tumors. Cure was established by CRISPR pioneers in 2016 to develop therapies for difficult-to-treat cancers and genetic diseases. Its CRISPR-mediated single or multiplex gene editing platform is aimed at producing more effective or safer cell therapy products, including universal CAR-T candidates. The financing round was led by Advantech Capital and joined by Oriza Holdings, Blue Ocean Private Equity and Qiming Venture Capital. More details....Share this with colleagues: